100 related articles for article (PubMed ID: 24635598)
21. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
[TBL] [Abstract][Full Text] [Related]
22. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
23. Re: Discovery and Validation of Novel Expression Signature for Postcystectomy Recurrence in High-Risk Bladder Cancer.
Chang SS
J Urol; 2015 Aug; 194(2):334. PubMed ID: 26195361
[No Abstract] [Full Text] [Related]
24. Opa interacting protein 5 acts as an oncogene in bladder cancer.
He X; Hou J; Ping J; Wen D; He J
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2221-2233. PubMed ID: 28752236
[TBL] [Abstract][Full Text] [Related]
25. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples.
Karavitakis M; Msaouel P; Michalopoulos V; Koutsilieris M
Anticancer Res; 2014 Jun; 34(6):2937-42. PubMed ID: 24922657
[TBL] [Abstract][Full Text] [Related]
26. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer.
Zhang S; Zhang G; Guo H
Tumour Biol; 2017 Jun; 39(6):1010428317703822. PubMed ID: 28621231
[TBL] [Abstract][Full Text] [Related]
27. Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.
Segovia C; Martínez-Fernández M; Dueñas M; Rubio C; López-Calderón FF; Costa C; Saiz-Ladera C; Fernández-Grajera M; Duarte J; Muñoz HG; de la Rosa F; Villacampa F; Castellano D; Paramio JM
Oncotarget; 2017 Feb; 8(6):10531-10542. PubMed ID: 28060766
[TBL] [Abstract][Full Text] [Related]
28. Downregulated KLK13 expression in bladder cancer highlights tumor aggressiveness and unfavorable patients' prognosis.
Tokas T; Avgeris M; Alamanis C; Scorilas A; Stravodimos KG; Constantinides CA
J Cancer Res Clin Oncol; 2017 Mar; 143(3):521-532. PubMed ID: 27858162
[TBL] [Abstract][Full Text] [Related]
29. [Clinical applications of molecular biomarkers in urothelial carcinoma of bladder].
Cheng L; Xu JW; He JJ; Zhao J; Teng XD
Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):714-7. PubMed ID: 22321559
[No Abstract] [Full Text] [Related]
30. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
31. Genomic profiling of advanced bladder cancer to guide the use of targeted therapeutics.
Green AK; Milowsky MI
Cancer; 2016 Mar; 122(5):676-7. PubMed ID: 26650963
[No Abstract] [Full Text] [Related]
32. Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer.
Kobayashi K; Matsumoto H; Matsuyama H; Fujii N; Inoue R; Yamamoto Y; Nagao K
Oncol Rep; 2016 Nov; 36(5):2852-2860. PubMed ID: 27599396
[TBL] [Abstract][Full Text] [Related]
33. Mononucleotide markers of microsatellite instability in carcinomas of the urinary bladder.
Saetta AA; Goudopoulou A; Korkolopoulou P; Voutsinas G; Thomas-Tsagli E; Michalopoulos NV; Patsouris E
Eur J Surg Oncol; 2004 Sep; 30(7):796-803. PubMed ID: 15296997
[TBL] [Abstract][Full Text] [Related]
34. Association of single nucleotide polymorphisms in promoter of matrix metalloproteinase-2, 8 genes with bladder cancer risk in Northern India.
Srivastava P; Kapoor R; Mittal RD
Urol Oncol; 2013 Feb; 31(2):247-54. PubMed ID: 21784671
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
Pietruszewska W; Bojanowska-Poźniak K; Kobos J
Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
[TBL] [Abstract][Full Text] [Related]
36. Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2.
Song T; Zhang X; Wang C; Wu Y; Dong J; Gao J; Cai W; Hong B
Asian Pac J Cancer Prev; 2011; 12(4):929-33. PubMed ID: 21790228
[TBL] [Abstract][Full Text] [Related]
37. A novel approach to using matrix metalloproteinases for bladder cancer.
Fernández CA; Wszolek MF; Loughlin KR; Libertino JA; Summerhayes IC; Shuber AP
J Urol; 2009 Nov; 182(5):2188-94. PubMed ID: 19758628
[TBL] [Abstract][Full Text] [Related]
38. FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Rinaldetti S; Wirtz R; Worst TS; Hartmann A; Breyer J; Dyrskjot L; Erben P
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1701-1709. PubMed ID: 29959570
[TBL] [Abstract][Full Text] [Related]
39. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Kim YJ; Kim WJ
Investig Clin Urol; 2016 Jun; 57 Suppl 1(Suppl 1):S77-88. PubMed ID: 27326410
[TBL] [Abstract][Full Text] [Related]
40. Association of tumour necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guérin immunotherapy.
Ahirwar DK; Mandhani A; Dharaskar A; Kesarwani P; Mittal RD
BJU Int; 2009 Sep; 104(6):867-73. PubMed ID: 19338536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
